治疗白癜风的药物开发，也在摸索之中。
“开发药物远比单纯的实验室研究更复杂、更艰难，需要的时间也更长。总之，后面的研究更难。”
“但难才有意思。” 陈婷补充道。
参考文献：
（上下滑动可浏览）
1. Taieb, A. & Picardo, M. Vitiligo. New England Journal of Medicine 360, 160-U100, doi:10.1056/NEJMcp0804388 (2009).
2. Picardo, M. et al. Vitiligo. Nature Reviews Disease Primers 1, 15011, doi:10.1038/nrdp.2015.11 (2015).
3. O'Shea, J. J. & Plenge, R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36, 542-550, doi:10.1016/j.immuni.2012.03.014 (2012).
4. Harris, J. E. et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J. Invest. Dermatol. 132, 1869-1876, doi:10.1038/jid.2011.463 (2012).
5. Chatterjee, S. et al. A quantitative increase in regulatory T cells controls development of vitiligo. J. Invest. Dermatol. 134, 1285-1294, doi:10.1038/jid.2013.540 (2014).
6. Agarwal, P. et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J. Invest. Dermatol. 135, 1080-1088, doi:10.1038/jid.2014.529 (2015).
7. Lang, K. S. et al. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J. Invest. Dermatol. 116, 891-897, doi:10.1046/j.1523-1747.2001.01363.x (2001).
8. Namazi, M. R. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected? Pigment Cell Res. 20, 360-363, doi:10.1111/j.1600-0749.2007.00408.x (2007).
9. Stromberg, S. et al. Transcriptional profiling of melanocytes from patients with vitiligo vulgaris. Pigment Cell & Melanoma Research 21, 162-171, doi:10.1111/j.1755-148X.2007.00429.x (2008).
10. Ganju, P. et al. Microbial community profiling shows dysbiosis in the lesional skin of Vitiligo subjects. Sci. Rep. 6, 18761, doi:10.1038/srep18761 (2016).
制版编辑 |
